Glucagon-Like Peptide-1 Receptor

"Glucagon-Like Peptide-1 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A receptor for GLUCAGON-LIKE PEPTIDE 1 (GLP-1) expressed primarily on the surface of beta and ductal exocrine cells of the pancreas, as well as cells of other tissues. GLP-1 acts through GLP-1R to potentiate signaling in pancreatic cells in response to glucose-stimulated insulin secretion (GSIS).

Descriptor ID	D000067757
MeSH Number(s)	D12.776.543.750.695.021.500 D12.776.543.750.750.360.100.500
Concept/Terms	Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide-1 Receptor Glucagon Like Peptide 1 Receptor Peptide-1 Receptor, Glucagon-Like Receptor, Glucagon-Like Peptide-1 GLP-1R Receptor GLP 1R Receptor Receptor, GLP-1R GLP1R Protein Protein, GLP1R GLP-1 Receptor GLP 1 Receptor Receptor, GLP-1 GLP1R Receptor Receptor, GLP1R

Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-1 Receptor".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, G-Protein-Coupled [D12.776.543.750.695]
Glucagon-Like Peptide Receptors [D12.776.543.750.695.021]
Glucagon-Like Peptide-1 Receptor [D12.776.543.750.695.021.500]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Gastrointestinal Hormone [D12.776.543.750.750.360]
Glucagon-Like Peptide Receptors [D12.776.543.750.750.360.100]
Glucagon-Like Peptide-1 Receptor [D12.776.543.750.750.360.100.500]

Below are MeSH descriptors whose meaning is related to "Glucagon-Like Peptide-1 Receptor".

Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-1 Receptor".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Glucagon-Like Peptide-1 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-1 Receptor" was a major or minor topic of these publications.

Bar chart showing 16 publications over 9 distinct years, with a maximum of 5 publications in 2022

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2013	0	2	2
2016	0	1	1
2017	0	1	1
2019	0	1	1
2020	1	0	1
2021	1	1	2
2022	1	4	5
2024	2	0	2
2025	0	1	1

Below are the most recent publications written about "Glucagon-Like Peptide-1 Receptor" by people in Profiles.

Vear A, Heneka MT, Clemmensen C. Incretin-based therapeutics for the treatment of neurodegenerative diseases. Nat Metab. 2025 Apr; 7(4):679-696.

View in: PubMed
Valdecantos MP, Ruiz L, Folgueira C, Rada P, Gomez-Santos B, Solas M, Hitos AB, Field J, Francisco V, Escalona-Garrido C, Zagmutt S, Calderon-Dominguez M, Mera P, Garcia-Martinez I, Maym?-Masip E, Grajales D, Alen R, Mora A, S?inz N, Vides-Urrestarazu I, Vilarrasa N, Arbones-Mainar JM, Zaragoza C, Moreno-Aliaga MJ, Aspichueta P, Fern?ndez-Veledo S, Vendrell J, Serra D, Herrero L, Schreiber R, Zechner R, Sabio G, Hornigold D, Rondinone CM, Jermutus L, Grimsby J, Valverde ?M. The dual GLP-1/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk. Nat Commun. 2024 11 28; 15(1):10342.

View in: PubMed
Patel R, Wadid M, Makwana B, Kumar A, Khadke S, Bhatti A, Banker A, Husami Z, Labib S, Venesy D, Fonarow G, Kosiborod M, Al-Kindi S, Bhatt DL, Dani S, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists Among Patients?With Overweight or Obesity,?Diabetes,?and HFpEF on SGLT2?Inhibitors. JACC Heart Fail. 2024 Nov; 12(11):1814-1826.

View in: PubMed
Bales MB, Centanni SW, Luchsinger JR, Fathi P, Biddinger JE, Le TDV, Nwaba KG, Paldrmic IM, Winder DG, Ayala JE. High fat diet blunts stress-induced hypophagia and activation of Glp1r dorsal lateral septum neurons in male but not in female mice. Mol Metab. 2022 10; 64:101571.

View in: PubMed
Cheng Z, Guo D, Ruzi A, Pan T, You K, Chen Y, Huang X, Zhang J, Yang F, Niu L, Xu K, Li YX. Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin. Cells. 2022 08 03; 11(15).

View in: PubMed
Al Rifai M, Vaughan EM, Abushamat LA, Lee M, Ramsey DJ, Gupta K, Navaneethan SD, Virani SS. Correlates of Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes Mellitus (from the Department of Veterans Affairs). Am J Cardiol. 2022 06 01; 172:7-10.

View in: PubMed
Chipkin SR. Tirzepatide for Patients With Type 2 Diabetes. JAMA. 2022 02 08; 327(6):529-530.

View in: PubMed
Mahtta D, Ramsey DJ, Lee MT, Chen L, Al Rifai M, Akeroyd JM, Vaughan EM, Matheny ME, Santo KRDE, Navaneethan SD, Lavie CJ, Birnbaum Y, Ballantyne CM, Petersen LA, Virani SS. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs. Diabetes Care. 2022 02 01; 45(2):372-380.

View in: PubMed
Roth J, Ashcroft FM, Wollheim CB, Kieffer TJ, Cherrington AD, Bergman RN, Taylor R, Najjar SM, Pedersen O, Ellingsgaard H, Holst JJ, Nauck MA, Kadowaki T, Czech MP, Corvera S, Saltiel AR, Corkey BE, Atkinson MA. Voices: Insulin and beyond. Cell Metab. 2021 04 06; 33(4):692-699.

View in: PubMed
Chang HY, Chou YY, Tang W, Chang GM, Hsieh CF, Singh S, Tung YC. Association of antidiabetic therapies with lower extremity amputation, mortality and healthcare cost from a nationwide retrospective cohort study in Taiwan. Sci Rep. 2021 03 26; 11(1):7000.

View in: PubMed

People

Explore

Similar Concepts

Top Journals